Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
Kintara Therapeutics (formerly DelMar Pharmaceuticals)
What Does Kintara Therapeutics (formerly DelMar Pharmaceuticals) Do?
DelMar Pharmaceuticals was a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Its lead product candidate was VAL-083, a 'first-in-class' small molecule chemotherapeutic. In 2020, DelMar Pharmaceuticals merged with Adgero Biopharmaceuticals Holdings, Inc., and the combined company was subsequently renamed Kintara Therapeutics, Inc. Kintara continues to advance VAL-083 for glioblastoma multiforme (GBM) and is also developing REM-001 for cutaneous metastatic breast cancer (CMBC). The company is dedicated to addressing unmet medical needs in oncology.
Where Is Kintara Therapeutics (formerly DelMar Pharmaceuticals)'s Headquarters?
HQ Function
Serves as the central hub for corporate operations, clinical development oversight, strategic planning, investor relations, and administrative functions for its oncology programs.
Notable Features:
Located within a prominent life sciences and biotechnology cluster in San Diego, providing access to a rich ecosystem of research institutions, talent, and potential collaborators.
Work Culture:
As a clinical-stage biopharmaceutical company, the culture is likely focused on scientific innovation, collaboration, and a sense of urgency to bring potential new therapies to patients. Emphasis on data-driven decision-making and regulatory compliance.
HQ Significance:
The San Diego headquarters is pivotal for Kintara's R&D strategy, clinical trial management, and engagement with the financial and scientific communities to support its drug development pipeline.
Values Reflected in HQ: The headquarters likely reflects values of innovation, scientific excellence, and a patient-focused mission, common in the biopharmaceutical industry.
Location:
Kintara Therapeutics, while headquartered in the United States, conducts its clinical trials on a global scale to access diverse patient populations and leading medical research institutions. This involves collaborations with contract research organizations (CROs) and clinical sites in North America, Europe, and potentially other regions to advance its oncology drug candidates like VAL-083 and REM-001. Their development strategy targets global regulatory approvals and commercialization.
Street Address:
9920 Pacific Heights Blvd., Suite 150
City:
San Diego
State/Province:
CA
Country:
USA
Where Else Does Kintara Therapeutics (formerly DelMar Pharmaceuticals) Operate Around the World?
Vancouver, British Columbia, Canada
Address: Information on a specific street address for a Canadian operational office post-merger is not readily available. DelMar Pharmaceuticals was originally incorporated in British Columbia and maintained operations there.
Canada offers a supportive environment for biotech research, including access to clinical trial sites and talent. A Canadian presence could facilitate these aspects, although Kintara's primary operational focus is now from its US headquarters.
Buying Intent Signals for Kintara Therapeutics (formerly DelMar Pharmaceuticals)
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Who's Leading Kintara Therapeutics (formerly DelMar Pharmaceuticals)? Meet the Executive Team
As of April 2025, Kintara Therapeutics (formerly DelMar Pharmaceuticals)' leadership includes:
Who's Investing in Kintara Therapeutics (formerly DelMar Pharmaceuticals)?
Kintara Therapeutics (formerly DelMar Pharmaceuticals) has been backed by several prominent investors over the years, including:
What Leadership Changes Has Kintara Therapeutics (formerly DelMar Pharmaceuticals) Seen Recently?
Kintara Therapeutics has seen some board-level changes and executive transitions typical for a company in its stage of development and post-merger integration. Specific announcements regarding executive hires or exits focus on strengthening its leadership for clinical advancement and strategic growth.
Departures
New Appointments:
What Technology (Tech Stack) Is Used byKintara Therapeutics (formerly DelMar Pharmaceuticals)?
Discover the tools Kintara Therapeutics (formerly DelMar Pharmaceuticals) uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Kintara Therapeutics (formerly DelMar Pharmaceuticals) Email Formats and Examples
Kintara Therapeutics likely uses common corporate email formats. Based on typical naming conventions, the most probable formats would involve the first name, last name, or initials combined with the company domain '@kintara.com'.
[first_initial][last]@kintara.com or [first].[last]@kintara.com
Format
rhoffman@kintara.com
Example
80%
Success rate
What's the Latest News About Kintara Therapeutics (formerly DelMar Pharmaceuticals)?
GlobeNewswire • January 29, 2024
Kintara Therapeutics News: Kintara Announces CEO Transition and Provides Corporate Update
Kintara Therapeutics announced that Saiid Zarrabian resigned as President, CEO, and Director. Robert E. Hoffman, a current director, was appointed President and CEO. The company also provided an update on its clinical programs....more
GlobeNewswire • November 13, 2023
Kintara Therapeutics News: Kintara Reports Financial Results for Fiscal First Quarter Ended September 30, 2023 and Provides Corporate Update
Kintara Therapeutics reported its financial results for the first fiscal quarter ended September 30, 2023, and provided updates on its ongoing clinical trials for VAL-083 in GBM and REM-001 in CMBC....more
Kintara Therapeutics Press Release • October 26, 2023
Kintara Therapeutics News: Kintara Provides Update on REM-001 Program
Kintara Therapeutics provided an update on its REM-001 program, highlighting the positive data from a prior Phase 2/3 study in CMBC patients and outlining plans for future development based on FDA feedback....more
Highperformr's free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Kintara Therapeutics (formerly DelMar Pharmaceuticals), are just a search away.